The drugmaker, which is run from Canonsburg, Pennsylvania, said it put "additional controls, corrective actions and improvements in place" at the facility in question to mitigate the perceived risk of product contamination several months prior to inspection. Extensive testing of the active pharmaceutical ingredients "was performed for the presence of nitrosamine impurities and no evidence of cross contamination was identified," according to Mylan. "We take very seriously our continued and comprehensive oversight of Mylan's entire manufacturing network." In July 2019, Mylan announced it would combine with Pfizer Inc.'s off-patent drug unit Upjohn in a deal that would reshape the generic drug industry. The merger is expected to close before year-end. A spokesperson for Pfizer declined to comment. Mylan bought some of its solvents from an outside company that's been banned from selling in the U.S., according to the FDA.